MiNK Therapeutics (NASDAQ:INKT) stock fell 30% on Monday, paring a massive 730% gain from Friday after William Blair downgraded the shares following the spectacular rally.

A research team led by Professor Takuya Yamamoto (Department of Life Science Frontiers) and Professor Yasuhiro Yamada at the University of Tokyo has developed a novel in vivo system that reveals how ...

MiNK Therapeutics surged on tumor remission data for agenT-797, but financial risks and limited clinical proof remain. Learn ...

Shares of MiNK Therapeutics (NASDAQ:INKT) tumbled 30% on Monday, erasing a large portion of the 730% surge seen on Friday after the company’s stock was downgraded by William Blair. The steep rally ...

Fraction, PDF, Vitamin C, Anticancer, Pancreatic Cancer, Cervical Cancer, Small-Cell Lung Cancer Share and Cite: Konno, S. , Penunuri, A. , Wong, J. , Fullerton, S. and Choudhury, M. (2025) Anticancer ...